<DOC>
	<DOCNO>NCT00055653</DOCNO>
	<brief_summary>RATIONALE : Umbilical cord blood transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill cancer cell . PURPOSE : Phase II trial study effectiveness allogeneic umbilical cord blood transplantation treat patient leukemia , lymphoma , nonmalignant hematologic disorder .</brief_summary>
	<brief_title>Donor Umbilical Cord Blood Transplantation Treating Patients With Leukemia , Lymphoma , Nonmalignant Hematologic Disorders</brief_title>
	<detailed_description>OBJECTIVES : - Determine 180-day survival patient malignant nonmalignant hematologic disease treat allogeneic umbilical cord blood transplantation . ( Severe aplastic anemia , Fanconi anemia , marrow failure syndromes stratum close accrual ; adult [ 18 year age ] patient stratum close accrual . ) - Determine disease-free long-term survival patient treat regimen . - Determine incidence neutrophil engraftment , primary secondary graft failure , platelet engraftment , red blood cell engraftment patient treat regimen . - Determine incidence severity acute chronic graft-versus-host disease patient treat regimen . - Determine incidence complication , include infection , veno-occlusive disease , interstitial pneumonitis , patient treat regimen . - Determine incidence relapse , malignancy , lymphoproliferative disorder , posttransplantation myelodysplasia patient treat regimen . - Determine immune reconstitution patient treat regimen . OUTLINE : This multicenter study . Patients group accord follow stratum : - Stratum I : Malignant disease , 5/6 6/6 HLA match , age 18 - Stratum II : Malignant disease , 4/6 HLA match , age 18 - Stratum III : Malignant disease , 3/6 HLA match , age 18 - Stratum IV : Malignant disease , 2/6 1/6 HLA match , age 18 - Stratum V ( closed accrual ) : Severe aplastic anemia , Fanconi anemia , marrow failure syndrome - Stratum VI : Inborn error metabolism/storage disease nonmalignant disease include stratum V - Stratum VII : Malignant disease receive alternative condition regimen comprise busulfan melphalan - Stratum VIII ( closed accrual ) : Adult patient ( age 18 ) - Conditioning therapy : Patients assign 1 5 group accord diagnosis . - Group I ( malignant disease severe aplastic anemia [ severe aplastic anemia close accrual ] ) : Patients undergo total body irradiation ( TBI ) twice daily day -8 -4 . Patients receive cyclophosphamide IV day -3 -2 , methylprednisolone IV day -3 0 , antithymocyte globulin ( ATG ) IV twice daily day -3 -1 . - Group II ( Fanconi anemia [ closed accrual ] ) : Patients undergo TBI day -6 , receive cyclophosphamide IV fludarabine IV day -5 -2 , methylprednisolone IV ATG IV day -5 -1 . - Group III ( inborn error metabolism/storage disease ) : Patients receive oral busulfan 4 time daily day -9 -6 , cyclophosphamide group II , methylprednisolone ATG group I . - Group IV ( nonmalignant disease ) : Patients receive condition therapy group III . Patients familial erythrophagocytic lymphohistiocytosis Langerhans cell histiocytosis also receive etoposide day -5 -3 . - Group V ( non-TBI regimen leukemia patient 2 year age ) : Patients receive oral busulfan 4 time daily day -8 -5 , melphalan IV day -4 -2 , methylprednisolone ATG group I . - Allogeneic umbilical cord blood transplantation : All patient undergo umbilical cord blood transplantation day 0 . Beginning day 0 1 , patient receive filgrastim ( G-CSF ) IV subcutaneously daily blood count recover . - Graft-versus-host disease prophylaxis : Patients receive cyclosporine ( IV oral ) begin day -3 -1 continue 1 year transplantation methylprednisolone twice daily begin day 1 continue blood count recover . Patients follow weekly 14 week , 100 day , 4 , 5 , 6 , 9 , 12 , 18 , 24 , 36 month . PROJECTED ACCRUAL : A total 360 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 follow hematologic malignancy : Acute myeloid leukemia ( AML ) * With without history myelodysplastic syndrome ( MDS ) Patients first complete remission ( CR ) ( great 5 % blast marrow ) translocation ( 8 ; 21 ) inv ( 16 ) allow provide failed firstline induction therapy Patients first CR ( great 5 % blast marrow ) translocation ( 15 ; 17 ) allow provide least 1 follow true : Failed firstline induction therapy Molecular evidence persistent disease No patient first CR Down syndrome Acute lymphoblastic leukemia ( ALL ) * , meet 1 follow criterion : Not first CR ( great 5 % blast marrow ) In first CR high risk define 1 following : Hypoploidy ( 44 chromosome ) Pseudodiploidy translocation molecular evidence ( 9 ; 22 ) , 11q23 , ( 8 ; 14 ) ( exclude BALL ) +MLL gene rearrangement One following elevate WBC level : WBC great 100,000/mm^3 6 12 month age WBC great 200,000/mm^3 10 17 year age WBC great 20,000/mm^3 18 year age ( adult [ 18 year age ] patient stratum close accrual ) Failed achieve CR 4 week induction therapy BALL first CR meet least 1 highrisk criterion specify No translocation ( 8 ; 14 ) No blast surface immunoglobulin CD10 negative Undifferentiated leukemia* Infant leukemia* Biphenotypic leukemia* Chronic myelogenous leukemia , meet 1 follow criterion : Accelerated phase Chronic phase At least 1 year diagnosis without identify match unrelated bone marrow donor AND unresponsive unable tolerate interferon Blast crisis* ( great 30 % promyelocytes plus blast marrow ) One follow MDS : Refractory anemia Refractory anemia ring sideroblast Refractory anemia excess blast ( RAEB ) RAEB transformation Chronic myelomonocytic leukemia Paroxysmal nocturnal hemoglobinuria Hodgkin 's nonHodgkin 's lymphoma beyond first CR fail primary induction therapy Tumor display chemosensitivity ( great 50 % reduction mass size recent therapy ) NOTE : *Patients third great medullary relapse refractory disease ( primary induction failure ) blast crisis receive study busulfan/melphalan condition regimen ) OR Diagnosis one follow nonmalignant disease : Acquired severe aplastic anemia ( stratum close accrual ) Unresponsive medical therapy antithymocyte globulin and/or cyclosporine Inborn error metabolism , include , limited following : Hurler 's syndrome Adrenoleukodystrophy MaroteauxLamy syndrome Globoid cell leukodystrophy Metachromatic leukodystrophy Fucosidosis Mannosidosis Fanconi anemia document increase chromosomal fragility assay meet 1 follow criterion ( stratum close accrual ) : Severe pancytopenia Absolute neutrophil count le 500/mm^3 Platelet count le 20,000/mm^3 Hemoglobin less 8 g/dL Morphologic evidence MDS clonal chromosomal abnormality Leukemia transformation Other marrow failure syndrome , include follow ( stratum close accrual ) : BlackfanDiamond syndrome unresponsive medical therapy Kostmann 's congenital agranulocytosis unresponsive medical therapy Congenital amegakaryocytic thrombocytopenia Thrombocytopenia absent radius Combined immune deficiency include , limited following : Severe combine immunodeficiency ( SCID ) WiskottAldrich syndrome Leukocyte adhesion defect ChediakHigashi disease Xlinked lymphoproliferative disease Adenosine deaminase deficiency Purine nucleoside phosphorylase deficiency Xlinked SCID Common variable immune deficiency Nezeloff 's syndrome Cartilage hair hypoplasia Reticular dysgenesis No active CNS leukemia ( cerebrospinal fluid WBC great 5/mm^3 malignant cell cytospin ) No SCID patient require cytoreduction No dyskeratosis congenita No primary myelofibrosis No grade 3 great myelofibrosis Familial erythrophagocytic lymphohistiocytosis patient must follow : Abnormal brain MRI Neurologic symptom Lymphocytes monocytes great 7/mm^3 cerebrospinal fluid No available 5/6 6/6 HLAmatched related donor PATIENT CHARACTERISTICS : Age 55 ( 18 close accrual ) Performance status Karnofsky 70100 % OR Lansky 50100 % ( patient 16 year old ) Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic SGOT less 5 time upper limit normal Bilirubin le 2.5 mg/dL Renal Creatinine normal age OR Creatinine clearance glomerular filtration rate great 50 % low limit normal Cardiovascular LVEF great 40 % rest must improve exercise* OR Shortening fraction great 26 % * NOTE : *If symptomatic Pulmonary DLCO great 45 % predicted* ( correct hemoglobin ) FEV_1 FEC great 45 % predict ( correct hemoglobin ) OR Room air oxygen saturation great 85 % * NOTE : *If symptomatic Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled viral , bacterial , fungal infection HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics More 12 month since prior allogeneic stem cell transplantation cytoreductive preparative therapy More 6 month since prior autologous stem cell transplantation Chemotherapy See Biologic therapy Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No prior enrollment study No continuous life support ( e.g. , mechanical ventilation ) within 1 year study transplantation ( patient inborn error metabolism )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
</DOC>